A comparison of methods of plasmapheresis for the treatment of late antibody mediated rejection in kidney transplant recipients
THERAPEUTIC APHERESIS AND DIALYSIS, cilt.27, sa.3, ss.428-434, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 3
- Basım Tarihi: 2023
- Doi Numarası: 10.1111/1744-9987.13937
- Dergi Adı: THERAPEUTIC APHERESIS AND DIALYSIS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, MEDLINE
- Sayfa Sayıları: ss.428-434
- Anahtar Kelimeler: antibody mediated rejection, kidney transplantation, plasmapheresis, rejection, HUMORAL REJECTION, ALLOGRAFT-REJECTION, PLASMA-EXCHANGE, RITUXIMAB, IMMUNOADSORPTION, OUTCOMES, THERAPY, RESCUE
- İstanbul Üniversitesi Adresli: Evet
Özet
Introduction We compared the outcomes associated with plasma exchange (PE), double filtration plasmapheresis (DFPP), or immunoadsorption (IA) in the treatment of late antibody mediated rejection (AMR). Methods Sixty-nine kidney transplantation (KTx) recipients with late AMR were retrospectively categorized according to management with PE (n = 30), DFPP (n = 22) or IA (n = 17). Allograft loss was compared across treatment groups by Kaplan-Meier analysis and Cox regression. Results Study groups were similar regarding age, sex, donor type, kidney function, donor specific antibodies, and post-KTx follow-up time. Five-year graft survival trended higher with IA (70.6%) compared to PE (36.7%) and DFPP (27.3%) (p = 0.06). In multivariate Cox regression, baseline eGFR (HR per ml/min/1.73 m(2) [95% CI]; 0.96 [0.94-0.99]), rituximab use (HR [95% CI]; 0.42 [0.21-0.84]), interstitial inflammation (i) (HR [95% CI]; 2.05 [1.13-3.69]), and transplant glomerulopathy (cg) (HR [95% CI]; 1.46 [1.13-1.87]) were associated with graft loss. Conclusion These results motivate the need for continued assessment of rituximab and plasmapheresis in larger studies.